[현대건강신문=여혜숙 기자] An analysis showed that the risk of developing shingles may increase significantly after vaccination with Corona 19. However, it is pointed out that a review of clinical significance is necessary as no significance was found in the analysis by vaccine order.
The National Academy of Medicine of the Republic of Korea (Director Kyu-Chang Wang), established with the goal of evaluating the causality of adverse events after vaccination with the Corona 19 vaccine, held the 3rd forum on the 28th following the 1st and 2nd forums. .
In this forum, research analysis on the association between COVID-19 vaccination and deep vein thrombosis (without thrombocytopenia), pulmonary embolism, shingles, and multiple sclerosis was explained.
First, as a result of confirming the association between corona 19 vaccination and ‘deep vein thrombosis (without thrombocytopenia) and pulmonary embolism’, it was difficult to confirm causality.
Gachon University Gil Hospital Professor Jeong Jae-hoon of the department of infectious medicine said, “There is no evidence to support causality in deep vein thrombosis in the previous analysis. Therefore, in this reanalysis, we evaluated the statistical relevance of domestic COVID-19 vaccination and deep vein thrombosis and pulmonary embolism by utilizing strict case definitions and two independent research methodologies.” An increase in the incidence of deep vein thrombosis and pulmonary embolism was not observed. This is consistent with the results of a number of studies conducted overseas and a meta-analysis that synthesized them.”
The association between vaccination against Corona 19 and the occurrence of shingles can be somewhat increased, but additional research is needed.
Cases of shingles after diagnosis of COVID-19 and cases of reactivation of the shingles virus after vaccination with COVID-19 were reported around the world, and it was necessary to conduct epidemiological analysis to determine the safety of vaccines according to the number of vaccines and vaccine types in Korea. .
To evaluate the association between the COVID-19 vaccine and herpes zoster, we checked the incidence of herpes zoster in Korea for about 10 years, and compared the expected and observed incidence rates of herpes zoster after vaccination with the COVID-19 vaccine.
In addition, using the Self-Controlled Case Series (SCCS) design, the ‘risk interval (1–28 days after vaccination)’ and In the event of shingles, the ‘control period (period excluding the risk period within the observation period)’, which is expected to be unrelated to the vaccine, was compared.
Professor Sohn Hyo-joo of the Department of Infectious Diseases at Uijeongbu Eulji University Hospital said, “As a result of the study, the crude incidence rate per 100,000 population has been continuously increasing since 2013, with 1164.1 in 2020 and 1211.2 in 2021. As a result of the SCCS analysis, the risk of developing shingles within 28 days after vaccination was found to increase significantly by 1.1 times.”
However, he explained that there was no significance in the analysis of each vaccine sequence, so it is necessary to review the clinical significance.
Professor Sohn said, “A significant increase in risk was observed in age groups and chronic disease companions in the small group analysis, indicating the need to manage risk factors for common shingles.” is needed,” he said.
Due to the lack of safety evidence for the relationship between COVID-19 vaccination and multiple sclerosis, an epidemiological analysis was performed on the risk of multiple sclerosis after vaccination in the entire population of Korea.
A self-control study design was applied to evaluate the association between COVID-19 vaccine and multiple sclerosis. When the observation period was 270 days after vaccination with COVID-19 vaccine and the risk interval was set as 1 to 30 days or 1 to 60 days after vaccination, the risk of occurrence was 0.91 and 0.71 times, respectively, compared to the control group, but statistically significant. Did not do it.
Even when sensitivity analysis was performed with various operational definitions of patients with multiple sclerosis, no increase in the risk of multiple sclerosis was observed after vaccination with the COVID-19 vaccine. There was no statistical significance in the results of subgroup analysis according to gender, age, type of vaccine recently received before onset, and comorbidity score.
Professor Kim Yoo-hwan of the Department of Neurology at Hallym University Sacred Heart Hospital said, “Considering the results of this study and the review of literature, the scientific evidence to date has been evaluated as insufficient to admit or deny the causality between the COVID-19 vaccine and multiple sclerosis. “he said.
“At this forum, we presented research and analysis results related to deep vein thrombosis, herpes zoster, and multiple sclerosis, which are of high interest to the public,” said Park Byeong-joo, head of the COVID-19 Vaccine Safety Research Center. showed that vaccination with Corona 19 did not increase the risk of occurrence, and shingles appeared to slightly increase the risk of occurrence, but additional research is needed for clinical significance.”
In addition, “I deeply sympathize with the pain and frustration of those who have suffered from adverse reactions since the corona 19 vaccine, and I especially offer deep consolation to those who have died and their families. We will continue to make efforts to make more accurate results in terms of scientific causality through continuous research on various diseases.”
